M

Myriad Genetics
D

MYGN

13.650
USD
0.29
(2.17%)
مغلق
حجم التداول
35,805
الربح لكل سهم
0
العائد الربحي
-
P/E
-11
حجم السوق
1,242,630,890
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    BDX
    BDX
    -1.360
    (-0.60%)
    226.450 USD
    D
    DGX
    -0.190
    (-0.12%)
    152.910 USD
    H
    HOLX
    0.850
    (1.19%)
    72.500 USD
    ILMN
    ILMN
    -0.860
    (-0.63%)
    135.070 USD
    L
    LH
    -0.760
    (-0.33%)
    227.900 USD
    TMO
    TMO
    1.18
    (0.22%)
    525.21 USD
    المزيد
الأخبار
المقالات

العنوان: Myriad Genetics

القطاع: Healthcare
الصناعة: Diagnostics & Research
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarkerdiscovery and companion diagnostic services to pharma and biotech companies.